Search results for: Market Access
Filter search results
Organisational Costs in the New NHS
1 April 1999
…claims that such costs rose following the introduction of the N H S internal market in 1990. The Conservative government introduced a number of initiatives to reduce these costs in…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
…US market may evolve. With respect to the European experience, the briefing looks at how the market for EMA-approved biosimilars in the area of erythropoietins (EPOs) and granulocyte-colony-stimulating-factors (G-CSFs) has…
Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
1 December 2017
This report explores the consequences of the exit of the United Kingdom (UK) from the European Union (EU) on public health in the UK and in the EU. It also…
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
…Pilot Part 3: Creating a Healthy Global Market for New Antibiotics Part 4: What Does the Antibiotics Market of the Future Look like? Mott, D.J., Hampson, G., Llewelyn, M.J. et…
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
Share this: Download publication Matthias Hofer Grace Hampson NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently…
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
…of these global companies is highest. With respect to sales, “the market value of NMEs for European companies is far lower than the market value for US companies even after…
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…overview of the current market, including Ames, effectiveness, local markets, frameworks and politics, and then offers predictions for the next decade. This book aims not only to understand and discuss…
OHE Lunchtime Seminar: Economic Evaluation for Decision-Making and the Value of Access to Individual Patient Data
13 February 2017, 12:00am
…those tasked with providing information to support policy making. This lecture will offer a health economics perspective on the value of access to individual patient-level data (IPD) to guide HTA-like…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…access to combination therapies, including the prevailing pricing models used in Europe. Key takeaways Combination therapies (CTs) can provide effective treatment options and improve patient outcomes, but the lack of…